As of 07 March 2023, the Health Technology Assessment Council (HTA Council) has completed the assessment and deliberation for the preliminary recommendation on dapagliflozin 10 mg single-dose film-coated tablets as add-on treatment for adults with Type 2 Diabetes Mellitus including those who have or are at high risk of cardiovascular disease and/or diabetic neuropathy.

The HTA Council hereby makes public its preliminary recommendation for the government financing of Dapagliflozin 10 mg acid single-dose film-coated tablets through its inclusion in the Philippine National Formulary (PNF).

Kindly see the full advisory:

Kindly see the evidence summary for the dapagliflozin assessment:

To keep updated on HTA news, visit our website:
Like and follow our FB page: